A long-term development and commercial manufacturing agreement has been signed between Shilpa Medicare Limited and Switzerland-based NXI Therapeutics AG, extending the Indian pharmaceutical company’s role in global biologics and specialty therapeutics manufacturing. The agreement covers comprehensive chemistry, manufacturing and controls development, process scale-up, GMP clinical supply, and commercial manufacturing support for NXI’s immunomodulatory program. The collaboration will run from early-stage development through commercialisation, establishing the company as a lifecycle manufacturing and development partner for the program.
The arrangement comes as autoimmune and immune-modulation therapies continue to attract growing industry attention because of increasing demand for targeted immunotherapies and rising prevalence of related disorders. By entering the program during its early development phase, the Indian CDMO strengthens its exposure to high-value pipelines with long-term commercial potential. The latest mandate also marks the third publicly announced partnership secured by the company within the past year, reflecting rising demand from Western biotechnology firms seeking integrated research, development and advanced GMP manufacturing support.
Financial details of the agreement were not disclosed. However, the companies stated that the partnership includes milestone-linked expansion opportunities and could develop into a multi-year commercial supply arrangement, subject to clinical progress and regulatory approvals. “This collaboration reinforces Shilpa Medicare’s transformation into a strategic innovation partner for global biotech companies. Our integrated development and commercial manufacturing capabilities enable us to support complex assets across the full product lifecycle. We continue to see strong momentum in high-value biologics and specialty therapeutics, strengthening long-term growth visibility for our CDMO platform,” said Mr. Vishnukanth Bhutada, Managing Director of the company.
Dr. Ruben Herrendorff, CEO of NXI Therapeutics AG, said: “Shilpa’s scientific depth, quality systems, and scalable GMP manufacturing capabilities make them an ideal partner as we advance our immunomodulatory program toward clinical and commercial milestones.” The agreement further strengthens the company’s biologics manufacturing presence, supported by expanding GMP infrastructure in India and increasing engagement with international biotechnology developers.
